Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.

BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...

Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.

Beam Therapeutics' pipeline, especially BEAM-101 for sickle cell disease, shows promise but remains in early stages with significant risks and high market expectations. Financially, BEAM has a ...

In the preceding three months, 4 analysts have released ratings for Beam Therapeutics (NASDAQ:BEAM), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...

Has Beam Therapeutics Inc. (BEAM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that ...